Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients (Chloroquine IV)
Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial
Sponsor: Maastricht Radiation Oncology
Terminated
Poor accrual
Other terminated trials from Maastricht Radiation Oncology
Other Small Cell Lung Cancer trials with similar outcome
This PHASE1 trial investigates Small Cell Lung Cancer and is currently terminated or withdrawn. Maastricht Radiation Oncology leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — May 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maastricht Radiation Oncology
- Maastricht University Medical Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .